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verrucous epidermal nevus (VEN) is a skin
disorder that commonly presents at birth and
is frequently resistant to multiple treatment
modalities.1 Physical therapeutic approaches have
been used, but recurrences are common, and topical
treatments seem to be ineffective.2 Here, we report a
case of recalcitrant VEN successfully treated with
photodynamic therapy (PDT) using indocyanine
green (ICG).
CASE REPORT
A 24-year-old woman visited our department with
cutaneous lesions associated with intermittent se-
vere pruritus. These lesions initially developed in
early childhood on the back of her left hand. On
physical examination, we observed a 5- 3 4-cm
erythematous verrucous plaque with scales and
abrasions, likely a result of irritation, on the back
of the left hand (Fig 1, A). A skin biopsy specimen of
the lesion showed hyperkeratosis, papillomatosis,
and acanthosis with elongation of the rete ridges.
Perivascular inflammatory cells such as lymphocytes
and histiocytes were observed in the dermis (Fig 2),
with a negative result on human papillomavirus
staining. The patient was diagnosed with an inflam-
matory VEN. She was treated with 3 sessions of
carbon-dioxide (CO2) laser treatment and topical
calcipotriol 0.005% plus betamethasone propionate
for 3 months. The Sharplan 20 C (Laser Industries,
Tel Aviv, Israel) was used for CO2 laser in super pulse
and continuous cutting modes, set to a wavelength
of 10,600 nm, 1-mm spot, and power output of 1 to 2
W. CO2 laser treatments resulted in a temporary
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ddal@hanmail.net.severe itching were observed, and there was recur-
rence a few months later. Considering the size of the
lesion and scar formation after treatments, we
attempted management with trichloroethane, 5-
fluorouracil, bleomycin, and cryotherapy. These
regimens led to a poor response with a volume
decrease of only 10% to 20%. Therefore, PDT was
initiated: 25 mg of ICG was applied in a 1-mm-thick
layer with a 5-mm margin of normal appearing skin.
Pretreatment with superficial CO2 ablation was
performed to smooth the verrucous lesion.
Ablation was achieved using a defocused 1-mm
beam and a low power output of 0.5 W with rapid
side-to-side hand movements. The ICG-treated area
was covered with an occlusive polyurethane film for
1 hour. The lesion was then treated with 2 passes of
intense pulsed light (IPL) (CIPL P-NAIN System,
Jeisys Medical Inc, Tokyo, Japan). The parameters
were wavelength of 550 to 800 nm, fluence of 23 J/
cm2, and 171 pulses in 12 milliseconds per shot. The
patient reported mild pain and itching during
treatment without any severe side effects. After 6
treatment sessions over 11 months, the cosmetic and
clinical responses were excellent, and the patient
was very satisfied (Fig 1, B). After 2 years of follow-
up, no recurrence has been observed.JAAD Case Reports 2015;1:312-4.
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Fig 1. A, A 5-3 4-cm erythematous verrucous plaque with scales and abrasions on the back of
the patient’s left hand. B, After 6 treatment sessions in 11 months, the cosmetic and clinical
response was excellent.
Fig 2. Skin biopsy specimen from a skin lesion showed
hyperkeratosis, papillomatosis, and acanthosis with elon-
gation of the rete ridges and perivascular inflammatory
cells in the dermis. (Hematoxylin-eosin stain; original
magnification: 340.)
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Epidermal nevi are a hamartomas of the skin and
have multiple clinical variants including a verrucous
type. AVEN consists of hyperplasia of the epidermis
and typically appears as verrucous papules or well-
demarcated papillomatous plaques that are skin-
colored to brown. These tumors can be located
anywhere, including the head, trunk, or extremities.3
The lesions on our patient appeared on an exposed
area, leading to cosmetic problems associated with a
reduced quality of life. A VEN usually has a poor
response to many different treatment modalities;
surgical excision has to date been the most reliable
treatment. However, surgical excision might not be
possible when a skin lesion is very extensive, and it
might cause scarring. Many other treatment modal-
ities have been reported, including topical agents,cryotherapy, lasers, electrofulguration, and chemical
peels, with various clinical outcomes.1,2 In this case,
the patient refused surgical excision because of
concerns of postoperative scarring. Combined treat-
ment with trichloroethane, 5-fluorouracil, bleomycin,
and cryotherapy produced a poor response. Given
the patient’s financial concerns, we chose the least
expensive photosensitizing agent, ICG, for PDT.
ICG has a known phototoxic effect in HaCaT
cells,4,5 which is a spontaneously transformed aneu-
ploid immortal keratinocyte cell line originating from
adult human skin. Based on the patient’s histologic
finding of epidermal hyperplasia, we assumed that
PDT using ICG would irradiate the proliferating
keratinocytes in the VEN. The epidermal nevus did
not have the factors that could intrinsically respond
to IPL alone (eg, excessive vascularity, melanin, or
hair components). Even though the absorption peak
of ICG was observed at 780 nm, there was spectral
absorption between 600 to 800 nm. In addition, we
used a wavelength range of 550 to 800 nm for IPL to
achieve the best effects of photoactivation. Thus, IPL
activated ICG at a range of wavelengths surrounding
the absorption peak.
PDT is primarily used for treatment of several
cutaneous nonmelanoma cancers. It is now being
increasingly used for treatment of a variety of other
skin diseases. Topical PDT has been used in inflam-
matory dermatoses including psoriasis, lichen scle-
rosus, and cutaneous sarcoidosis, with good
response.6-8 ICG is a water-soluble tricarbocyanine
dye with a peak spectral absorption at 780 nm, and
its intravenous application has been Food and Drug
Administrationeapproved since 1959 for determina-
tion of cardiac output, liver function diagnostics, and
ophthalmic angiography. There are various reports
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treatment of mild to moderate acne, augmentation of
the therapeutic effect of diode lasers in port-wine
stains, and PDT of actinic keratosis. Compared with
conventional photosensitizers, such as aminolevu-
linic acid and methylaminolevulinic acid, ICG is
considered a good alternative material with minimal
side effects and fair therapeutic efficacy.9,10
Based on the presented case, PDT using ICG has
substantial advantages in treating a VEN. It is less
painful, leads to less scarring, and can be used to
treat widespread areas relatively inexpensively. In
addition, photoprotection with ICG is not necessary
as its spectral absorption is in the near-infrared
range. Treatment with PDT using ICG produced
similar results to 2 previous case reports, in which
verrucous epidermal nevi were treated with PDT
using methylaminolevulinic acid.1,2 PDT may be
shown to be a useful tool to treat verrucous
epidermal nevi. To date, there have been no reports
of VEN successfully treated with PDT using ICG, and
further controlled studies with a large number of
patients and long-term follow-up are needed.
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